RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Metabolomic patterns, redox-related genes and metals, and bone fragility endpoints in the Hortega Study
[EN] Background: The potential joint influence of metabolites on bone fragility has been rarely evaluated. We assessed the association of plasma metabolic patterns with bone fragility endpoints (primarily, incident osteoporosisrelated bone fractures, and, secondarily, bone mineral density BMD) in the Hortega Study participants. Redox balance plays a key role in bone metabolism. We also assessed differential associations in participant subgroups by redox-related metal exposure levels and candidate genetic variants. Material and methods: In 467 participants older than 50 years from the Hortega Study, a representative sample from a region in Spain, we estimated metabolic principal components (mPC) for 54 plasma metabolites from NMR-spectrometry. Metals biomarkers were measured in plasma by AAS and in urine by HPLC-ICPMS. Redoxrelated SNPs (N = 341) were measured by oligo-ligation assay. Results: The prospective association with incident bone fractures was inverse for mPC1 (non-essential and essential amino acids, including branched-chain, and bacterial co-metabolites, including isobutyrate, trimethylamines and phenylpropionate, versus fatty acids and VLDL) and mPC4 (HDL), but positive for mPC2 (essential amino acids, including aromatic, and bacterial co-metabolites, including isopropanol and methanol). Findings from BMD models were consistent. Participants with decreased selenium and increased antimony, arsenic and, suggestively, cadmium exposures showed higher mPC2-associated bone fractures risk. Genetic variants annotated to 19 genes, with the strongest evidence for NCF4, NOX4 and XDH, showed differential metabolic-related bone fractures risk. Conclusions: Metabolic patterns reflecting amino acids, microbiota co-metabolism and lipid metabolism were associated with bone fragility endpoints. Carriers of redox-related variants may benefit from metabolic interventions to prevent the consequences of bone fragility depending on their antimony, arsenic, selenium, and, possibly, cadmium, exposure levels., Funding statement The work was funded by theo State Research Agency at the Ministerio de Ciencia Innovacion y Universidades of Spain (PID2019-108973RB-C21, PID2019-108973RB-C22 and PCIN-2017-117) ; the Generalitat Valenciana of Spain (IDIFEDER/2021/072, GRUPOS 03/101, PROMETEO/2009/029, ACOMP/2013/039, IDIFEDER/2021/072 and GRISOLIAP/2021/119) ; the EU Joint Programming Initiative Healthy Diet Healthy Life (HDHL) GUTMOM (INTIMIC-085) ; the Strategic Action for Research in Health sciences [CP12/03080, PI15/00071, PI10/0082, PI13/01848, PI14/00874, PI16/01402, PI17/00544 and PI11/00726] ; CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN) (CIBER-02-08-2009, CB06/03 and CB12/03/30016) ; the Castilla-Leon Government (GRS/279/A/08) and European Network of Excellence Ingenious Hypercare (EPSS-037093) from the European Commission. The Strategic Action for Research in Health sciences and CIBEROBN are initiatives from Carlos III Health Institute Madrid and co-funded with European Funds for Regional Development (FEDER) . M.G-P received the support of a fellowship from "la Caixa" Foundation (ID 100010434, fellowship code LCF/BQ/IN18/11660001) . The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 PCIN-2017-117
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-108973RB-C21
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-108973RB-C22
,
European Commission / H2020 727565
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI17/00544
,
Junta de Castilla y León GRS 279/A/08
,
Ministerio de Ciencia e Innovación PI11/00726
,
Ministerio de Economía y Competitividad CP12/03080
,
Ministerio de Economía y Competitividad PI13/01848
,
Ministerio de Economía y Competitividad PI14/00874
,
Ministerio de Economía y Competitividad PI15/00071
,
Ministerio de Economía y Competitividad PI16/01402
,
Ministerio de Sanidad y Consumo CB06/03/0016
,
Generalitat Valenciana IDIFEDER/2021/072
,
Generalitat Valenciana GRUPOS 03/101
,
Generalitat Valenciana PROMETEO/2009/029
,
Generalitat Valenciana ACOMP/2013/039
,
Generalitat Valenciana GRISOLIAP/2021/119
,
Instituto de Salud Carlos III PI10/0082
,
Fundació Bancària Caixa d'Estalvis i Pensions de Barcelona LCFLCF/BQ/DI18/11660001
,
European Molecular Biology Organization EPSS-037093